First report of tirofiban-induced anemia (Found in combination with severe thrombocytopenia)

Texas Heart Institute Journal

Volumn 36, Issue 1, 2009, Pages 55-57

  Sakellariou, Dimitris ^a   Pastromas, Socrates ^a   Koulouris, Spyridon ^a   Manolis, Antonis S ^a  

^a EVANGELISMOS HOSPITAL   (Greece)

Author keywords

Anemia; Platelet aggregation inhibitors; Platelet glycoprotein GPIIb IIIa complex drug effects; Thrombocytopenia; Tirofiban

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; HEPARIN; IMMUNOGLOBULIN G; TIROFIBAN;

ADULT; ANAMNESIS; ANEMIA; ANGIOCARDIOGRAPHY; ARTICLE; AUTOIMMUNITY; CASE REPORT; CATHETERIZATION; CLINICAL FEATURE; CONTINUOUS INFUSION; CORONARY ARTERY CIRCUMFLEX BRANCH; CORONARY ARTERY OBSTRUCTION; DISEASE COURSE; DISEASE SEVERITY; DRUG ELUTING STENT; DRUG WITHDRAWAL; HEART INFARCTION; HEMATOCRIT; HOSPITAL DISCHARGE; HUMAN; LOADING DRUG DOSE; MALE; MICROSCOPY; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; RIGHT CORONARY ARTERY; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TRANSLUMINAL CORONARY ANGIOPLASTY;

ACUTE DISEASE; ANEMIA; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; SEVERITY OF ILLNESS INDEX; THROMBOCYTOPENIA; TIME FACTORS; TREATMENT OUTCOME; TYROSINE;

EID: 65749111043     PISSN: 07302347     EISSN: 15266702     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Karvouni E, Katritsis DG, Ioannidis JP. Intravenous glycoprotein IIb/IIIa receptor antagonists reduce mortality after percutaneous coronary interventions. J Am Coll Cardiol 2003;41(1):26-32.
2. Abrams CS, Cines DB. Thrombocytopenia after treatment with platelet glycoprotein IIb/IIIa inhibitors. Curr Hematol Rep 2004;3(2):143-147
3. Dasgupta H, Blankenship JC, Wood GC, Frey CM, Demko SL, Menapace FJ. Thrombocytopenia complicating treatment with intravenous glycoprotein IIb/IIIa receptor inhibitors: a pooled analysis. Am Heart J 2000;140(2):206-211
4. Merlini PA, Rossi M, Menozzi A, Buratti S, Brennan DM, Moliterno DJ, et al. Thrombocytopenia caused by abciximab or tirofiban and its association with clinical outcome in patients undergoing coronary stenting. Circulation 2004;109(18):2203-2206
5. Tcheng JE. Clinical challenges of platelet glycoprotein IIb/IIIa receptor inhibitor therapy: bleeding, reversal, thrombocytopenia, and retreatment. Am Heart J 2000;139(2 Pt 2):S38-45.
6. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators [published erratum appears in N Engl J Med 1998;339(6):415]. N Engl J Med 1998;338(21):1488-1497
7. Huxtable LM, Tafreshi MJ, Rakkar AN. Frequency and management of thrombocytopenia with the glycoprotein IIb/IIIa receptor antagonists. Am J Cardiol 2006;97(3):426-429
8. Aster RH. Drug-induced immune thrombocytopenia: an overview of pathogenesis. Semin Hematol 1999;36(1 Suppl 1):2-6.
9. Madan M, Berkowitz SD. Understanding thrombocytopenia and antigenicity with glycoprotein IIb-IIIa inhibitors. Am Heart J 1999;138(4 Pt 2):317-326
10. Bougie DW, Wilker PR, Wuitschick ED, Curtis BR, Malik M, Levine S, et al. Acute thrombocytopenia after treatment with tirofiban or eptifibatide is associated with antibodies specific for ligand-occupied GPIIb/IIIa. Blood 2002;100(6):2071-2076